Skip to search formSkip to main contentSkip to account menu

givinostat

Known as: Gavinostat 
An orally bioavailable hydroxymate inhibitor of histone deacetylase (HDAC) with potential anti-inflammatory, anti-angiogenic, and antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (1)

Carbamates
ITF 2357NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Novel Therapies in Polycythemia Vera
Purpose of Review Polycythemia vera is a myeloproliferative neoplasm characterized by increased erythrocyte count, thrombotic… 
2019
2019
Correction to: Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma
In the original publication, the 6th author’s first name and the last name was inverted and incorrectly published. The correct… 
2017
2017
A Two-Part Study of Givinostat in Patients with Polycythemia Vera: The Maximum Tolerated Dose Selection and the Proof of Concept Final Results
Background and purpose of the study: Several reports have documented that histone deacetylase inhibitors induce neoplastic cells… 
Review
2017
Review
2017
Investigational drugs for treatment of juvenile idiopathic arthritis
ABSTRACT Introduction: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. The… 
2016
2016
Givinostat exhibits in vitro synergy with posaconazole against Aspergillus spp.
In vitro interactions of givinostat, a hydroxamate-derived histone deacetylase inhibitor, and antifungals including itraconazole… 
Review
2015
Review
2015
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases
Neurodegenerative diseases (NDs) are among the most feared of the disorders that afflict humankind for the lack of specific… 
2014
2014
Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study
Induction of fetal haemoglobin (HbF) is a promising therapeutic approach for the treatment of β‐thalassaemia and sickle cell… 
2011
2011
A Phase II Study of the HDAC Inhibitor Givinostat In Combination with Hydroxyurea In Patients with Polycythemia Vera Resistant to Hydroxyurea Monotherapy
Abstract 1748 [][1] Background and purpose. Several agents inhibiting the JAK2V617F mutation are actively investigated in… 
2011
2011
MiR-146a up-Regulation Is Associated with Anti-Tumor Activity of Pan-Histone Deacetylase Inhibitor ITF2357 (Givinostat®) in Human Burkitt's Lymphoma
Abstract 2729 Histone deacetylase inhibitors (HDACis) are among the most promising novel classes of anti-cancer compounds thanks… 
2010
2010
Safety and clinical activity of the histone deacetylase inhibitor givinostat in combination with meclorethamine in relapsed/refractory Hodgkin lymphoma (HL).
3068 Background: Encouraging safety and clinical activity of givinostat (ITF2357, Italfarmaco, Italy, EU) in combination with the… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)